Repare Therapeutics Inc. (NASDAQ:RPTX) CEO Sells $12,693.50 in Stock

Repare Therapeutics Inc. (NASDAQ:RPTX) CEO Lloyd Mitchell Segal sold 2,650 shares of the business’s stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $4.79, for a total transaction of $12,693.50. Following the transaction, the chief executive officer now directly owns 89,166 shares in the company, valued at $427,105.14. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Lloyd Mitchell Segal also recently made the following trade(s):

• On Wednesday, March 27th, Lloyd Mitchell Segal sold 2,650 shares of Repare Therapeutics stock. The shares were sold at an average price of $4.63, for a total transaction of $12,269.50.

Repare Therapeutics Trading Up 3.1 %

NASDAQ RPTX opened at $4.67 on Thursday. The company has a fifty day simple moving average of $6.33 and a 200 day simple moving average of $6.60. The company has a market cap of $172.79 million, a P/E ratio of -2.09 and a beta of 0.62. Repare Therapeutics Inc. has a 1 year low of $3.08 and a 1 year high of $13.85.

Repare Therapeutics (NASDAQ:RPTX) last posted its quarterly earnings data on Wednesday, February 28th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.11). The firm had revenue of $13.05 million for the quarter, compared to the consensus estimate of $15.92 million. Repare Therapeutics had a negative return on equity of 39.82% and a negative net margin of 183.43%. Equities research analysts forecast that Repare Therapeutics Inc. will post -2.74 EPS for the current fiscal year.

Institutional Trading of Repare Therapeutics

Several large investors have recently modified their holdings of RPTX. Barclays PLC bought a new stake in shares of Repare Therapeutics during the 2nd quarter worth $36,000. Deutsche Bank AG bought a new position in shares of Repare Therapeutics during the 4th quarter worth about $40,000. UBS Group AG increased its holdings in shares of Repare Therapeutics by 26.3% during the 3rd quarter. UBS Group AG now owns 3,551 shares of the company’s stock worth $43,000 after purchasing an additional 739 shares during the period. Wells Fargo & Company MN raised its position in shares of Repare Therapeutics by 185.8% during the fourth quarter. Wells Fargo & Company MN now owns 3,041 shares of the company’s stock valued at $45,000 after buying an additional 1,977 shares during the last quarter. Finally, SRS Capital Advisors Inc. bought a new stake in shares of Repare Therapeutics in the first quarter valued at about $49,000. 85.09% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

RPTX has been the subject of several recent research reports. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Repare Therapeutics in a research report on Wednesday, February 21st. Bloom Burton downgraded shares of Repare Therapeutics from a “buy” rating to an “accumulate” rating in a research report on Tuesday, February 13th.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.